LIEGE, Belgium—In another bow to the growing market for companion diagnostics, OncoMethylome Sciences announced it entered into a collaboration with GSK Biologicals to develop DNA methylation biomarkers for use as potential diagnostic tools alongside cancer immunotherapeutics developed by GSK. Financial details of the agreement were not disclosed, but it is supported by a Wallonia (BioWin) research grant OncoMethylome announced earlier in the year.

 

"We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals," says Dr. Jim DiGuiseppi, OncoMethylome CTO.

 

According to a June 2006 report entitled Companion Diagnostic Products and Individual Therapies, the market for molecular diagnostics would surpass $7 billion in 2006 and was projected to reach $35 billion by 2015.